UT-MD Anderson Cancer Center: ESMO - Pre- and Post-Surgical Immunotherapy Improves Outcomes for Patients With Operable Lung Cancer
October 23, 2023
October 23, 2023
HOUSTON, Texas, Oct. 23 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone
* * *
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy - given before and after surgery - significantly i . . .
* * *
Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone
* * *
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy - given before and after surgery - significantly i . . .